Крайний срок подачи заявок – 16 февраля 2016 года
SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient
Actions that focus on enabling the transition to new services or better integration of existing services through appropriate ICT based technologies using relevant elements e.g., proof of concept, user acceptance, use of the service, training of the professionals including online courses/forums that bring professionals and patients together, trust and security and consent of the patient. These strategies should allow communication to happen by increasing the level of interactions between the patient and the health professionals or informal carers, sharing of data and enabling the users to stay in control of their health condition and to adhere to prescribed medical plans and contribute to increasing the effectiveness of interventions.
Финансирование: 4 млн. евро.
SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing
This topic will contribute to the Scaling Up Strategy23 of the European Innovation Partnership on Active and Healthy Ageing and to boosting the Silver Economy and Digital Single Market in Europe. The actions supported will target deployment of active and healthy ageing solutions at large scale across different regions in Europe.
Финансирование: 4 млн. евро.
SC1-PM-18–2016: Big Data supporting Public Health policies
Rather than improving existing isolated systems, proposals should focus on how to better acquire, manage, share, model, process and exploit the huge amount of data to develop integrated solutions that support public health authorities of Member States and associated countries in particular in healthcare system management, long-term policy making and increase the ability to provide actionable insights at the point of care. Relevant solutions include, for example, systems for determining and monitoring the combined effects of environment, lifestyle and genetics on public health, enabling early identification of effects, both on women and men, that can have large impacts on health including lifestyle and provision of healthcare – both short term and long term as well as when interaction with other public sectors is required (e.g. physical planning). Focus should also be on the governance of Big Data in order to use it proficiently across organisations and at policy levels. Integrated solutions should include suitable approaches towards securing security and privacy issues.
Финансирование: 3-5 млн. евро.
SC1-HCO-09–2016: EU m-Health hub including evidence for the integration of mHealth in the healthcare systems
The core activities of the ‘innovation hub for mHealth’ should focus on fostering research and innovation in mHealth and bolster policy making efforts in implementing mHealth strategies tailored to the need of the European countries and regions involved.
The hub should act as a convening platform to bring together experts and innovators for institutionalising best practices in mHealth whilst avoiding the creation of silos and fragmentation in mHealth knowledge across the EU.
Emphasis should be put on the development of a multi-stakeholder ecosystem targeted at increasing collaboration between various stakeholders such as researchers, national, regional, local authorities, and mHealth manufacturers, supported by a central resource that tracks innovation and best practices and identifies gaps in policy while fostering cross-border knowledge sharing among Member States or countries associated to Horizon 2020.
Финансирование: 3 млн. евро.
SC1-HCO-10–2016: Support for Europe’s leading Health ICT SMEs
The scope is co-ordinating post R&D and offering support for developing business models, improving the maturity of the new products emerging from Europe’s leading Health ICT SMEs, developing a pro-innovation approach to address legal conditions in Europe and globally on a case-by-case basis.
Финансирование: 3 млн. евро
SC1-HCO-11–2016: Coordinated action to support the recognition of Silver Economy opportunities arising from demographic change
This shall be achieved by establishing a widely recognised European annual award scheme for innovative solutions which can demonstrate a significant impact improving the quality of life of the ageing population, for both women and men, and sustaining a viable and promising business model.
This Annual award will bring together all relevant societal actors and economic sectors to create a pan-European movement that acknowledges and exploits the opportunities brought about by demographic change and innovation.
Финансирование: 1 млн. евро
SC1-HCO-12–2016: Digital health literacy
Proposals should provide support for the improvement of digital health literacy of citizens. In particular, proposals should design open access online courses ("MOOCs") for different population cohorts including children and the elderly and other high-risk patient groups, supporting an interactive learning environment. These courses should ensure user-friendliness and involve citizens to co-design, test and implement learning modules that would help them improve their digital health literacy skills. The courses should be designed tailored to users' needs based on a strong understanding and projections of key factors, drivers, barriers and trends of the future that affect digital health literacy, be targeted specifically to citizens with low levels of digital health literacy and take into account and quantifying demographic, social, cultural and gender differences and address critical and/or interactive skills and competencies, as well as support peer learning. The work should also articulate a roadmap roll-out, simulate system level changes and detail the most appropriate policy actions for ongoing enablement.
Финансирование: 2 млн. евро.
SC1-HCO-13-2016: Healthcare Workforce IT skills
Proposals should focus on mapping, quantifying and projecting the need, supply and demand of workforce skills and competencies to develop IT skills and training programmes for the healthcare workforce taking into account the EU-US collaboration underway in this area under the EU-US MoU eHealth Roadmap41 and other international cooperation in this area. The work should identify how key factors and trends will be investigated, the different scenarios the system and eHealth workforce face, quantify and model these futures as well as describe how the most robust policies to deliver the desired impacts and outcomes will be investigated. They should also demonstrate knowledge of systematic workforce investigations including skills and competences existing curricula and training, identify gaps and propose solutions to bridge them. A series of case studies in some of the areas where IT already has an impact on the provision of health services, will support the proposed solutions in the most critical areas for example in primary health care, monitoring of chronic diseases, high risk patient care and geriatry. A familiarity with the ICT Skills’ European eCompetence Framework for healthcare is also important.
Финансирование: 0,5 млн. евро.
SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment
The proposal should aim at the establishment of a sustainable European Conformance Assessment Scheme associated with the maintenance of the eEIF, fostering a wider eHealth interoperability uptake for the entire European market.
Финансирование: 1 млн. евро.
SC1-HCO-16-2016: Standardisation needs in the field of ICT for Active and Healthy Ageing
The proposal is expected to foster user-centred ICT innovation on AHA by engaging, supporting and coaching stakeholders to develop and implement their actions in the area of standardisation. They should cover standardisation within the area of AHA, in particular in the domains of ICT infrastructures for the implementation and delivery of services for independent living in age-friendly buildings, scaling-up of innovative care services and interoperability profiles for independent living.
Финансирование: 1 млн. евро. \
Крайний срок подачи заявок – 13 апреля 2016 года
SC1-PM-01-2016: Multi omics for personalised therapies addressing diseases of the immune system
The scope of this topic is to integrate and use high quality genome, epigenome, proteome, metabolome, microbiome data produced by large scale international initiatives with innovative imaging, functional, structural and lifestyle/environmental data, and combine these with disease-oriented functional analysis to contribute to the understanding of health and disease with the final objective of selecting relevant biomarkers for clinical validation that will lead to the development of new targeted therapies for diseases of the immune system. Proposals must build on data from IHEC and, as appropriate, on data from other international initiatives. Proposals should address relevant ethical implications, take into account sex and gender differences and include a section on research data management. International cooperation is requested. Proposals addressing rare diseases of the immune system are excluded.
Финансирование: 12-15 млн.евро
SC1-PM-04–2016: Networking and optimising the use of population and patient cohorts at EU level
Proposals should aim at maximizing the exploitation of cohorts by bringing together national and/or European cohorts with common scientific interests (e.g. across diseases, children, mothers, elderly, birth, gender, etc.), and by taking advantage of new technologies (e.g. ICT, social platforms, etc.) and new type of data (e.g. geographical, genetic, eHealth records, etc.). Based on those cohorts using a comprehensive integration strategy to facilitate hypothesis-driven research, data sharing, harmonisation and analysis, proposals should provide expanded resources and knowledge on health and disease determinants, onset and course of diseases (including aspects of co-morbidity and/or co-infections), clinical, public health and socio-economic research. Synergies with relevant existing European infrastructures and additional collaborations with relevant international initiatives are encouraged. Proposals should also engage with relevant international/national/regional authorities to ensure that findings are implemented and translated into health policy.
Финансирование: 8-10 млн. евро.
SC1-PM-05–2016: The European Human Biomonitoring Initiative
The objective is to create a European joint programme for monitoring and scientific assessment of human exposures to chemicals and potential health impacts in Europe, building on previous activities undertaken at EU and national levels.
Финансирование: 50 млн. евро.
SC1-PM-06–2016: Vaccine development for malaria and/or neglected infectious diseases
Proposals will have to address bottlenecks in the discovery, preclinical and early clinical development of new vaccine candidates (antigens/adjuvants) for malaria and/or neglected infectious diseases. Filoviral diseases are specifically excluded from this topic.
Depending on the maturity of the research landscape for each disease, proposals may range from large research platforms developing multiple vaccine candidates and/or vaccines for multiple diseases, to proposals specifically focused on one disease.
Финансирование: 3-5 млн. евро на среднемасштабные исследования, 15-20 млн. евро на крупномасштабные исследования.
SC1-PM-09–2016: New therapies for chronic diseases
Proposals should focus on clinical trial(s), supporting proof of concept of clinical safety and efficacy in humans16 of novel therapies (pharmacological as well as non-pharmacological) or the optimisation of available therapies (e.g. repurposing) for chronic non-communicable or chronic infectious diseases. Preclinical research should be completed before the start of the project. Proposals should provide a sound feasibility assessment, justified by available publications or provided preliminary results. Gender and age must be considered whenever relevant. Due consideration should also be paid to involve patients and take their views into account wherever relevant. Rare diseases and regenerative medicine are not within the scope of this topic.
Финансирование: 4-6 млн. евро.
SC1-PM-11–2016-2017: Clinical research on regenerative medicine
Proposals should target regenerative medicine therapies which are ready for clinical (in-patient) research and should focus on one specific clinical phase of work. Any stage of clinical work (e.g., first in man, late stage trial, observational study) may be proposed though later stages are preferred; clinical work should represent the core of the proposal. To justify the clinical work proposed, phase I proposals must present appropriate preclinical and toxicology data, and later phase proposals must present appropriate preliminary results.
Proposals should include authorization to conduct clinical trials and ethical approvals or provide evidence of regulatory engagement and that such approval is close. Preference will be given to proposals which are closest to having approvals in place for clinical work to start. Since the objective is to test new regenerative therapies, proposals may address any disease or condition but a justification for the choice must be provided. Proposers should also justify why the therapy proposed is regenerative and how it represents a new approach compared to any existing treatment. Sex and gender differences should be investigated, where relevant. To allow an adequate coverage in the field of regenerative medicine, proposals should take into account the projects previously funded under this topic in Horizon 2020
Финансирование: 4-6 млн. евро.
SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries
Based on the concept of implementation research, proposals should seek to replicate and scale up a comprehensive intervention in the field of health systems that is innovative and well-researched, supported by sufficient documented evidence. This scaling up can take place within Europe as well as outside it, notably in low- and middle-income countries (LMIC). The topic does not cover micro-level interventions, e.g. to promote a specific therapeutic regimen for a single disease.
The selected intervention to be scaled up should be one that has proven to make health systems and health services more responsive, person-centred, safe, effective, and efficient. Its stated impact should be broad, addressing economic and social benefits and its effect on reducing inequalities. The research should identify the facilitators of and barriers to scaling-up, including context-specific factors and differing social and health systems environments in Europe or in LMIC.
Финансирование: 4-6 млн. евро.
SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results
The objective of this coordination and support action is to develop a European web marketplace referencing all types of innovations such as patents, licensing opportunities, prototypes, products, technologies or services with a potential for future exploitation and/or commercialisation, primarily generated by FP7 Health and Horizon 2020 SC1 programmes.
Финансирование: 1-2 млн. евро.
SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine
Provide pan-European quality assurance schemes and guidelines for pre-analytical procedures - such as sample collection, handling, transportation, processing and storing of clinical samples - and/or harmonisation and quality assurance of diagnostic practice.
The proposal should contribute to accreditation and certification, and participate in standardization activities at European level. Interaction with the European Metrology Programme for Innovation and Research (EMPIR) should be considered as appropriate. Outcomes could be coordination of validation studies, assessment of the results of method validations, training, counselling, quality procedures and guidelines.
Финансирование: 2 млн. евро.
SC1-HCO-04–2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance
Proposals should support the development and extension of the Joint Programming Initiative on antimicrobial resistance capacities.
Финансирование: 1-2 млн. евро.
SC1-HCO-05–2016: Coordinating personalised medicine research
Support the development and operations of a European platform for collaboration between funders of personalised medicine research, possibly based on the International Consortium model. The platform should coordinate research and innovation efforts across borders, regions and countries. It should foster an interdisciplinary approach to personalised medicine by actively involving relevant interested parties. It should develop policies, guidelines, etc. aiming to speed up the development and implementation of personalised medicine (addressing policy-related, economic, and socio-cultural factors). The platform should aim to create synergies with ongoing activities at European and national level (e.g. research infrastructures, ERA-NETs, personalised medicine pilot projects, EIT Health KIC). It should moreover explore the best use of funds in the implementation of personalised medicine. It should actively disseminate information and best-practice examples and contribute to awareness raising in the medical professions (accelerating the reshaping of academic curricula) and among the general public. The proposal should explore scenarios for long-term sustainability.
Финансирование: 2 млн. евро.
SC1-HCO-06–2016: Towards an ERA-NET for building sustainable and resilient health system models
To pave the way to an ERA-NET co-fund action for building sustainable and resilient health systems models, this coordination and support action (CSA) will develop a structured system of exchange of information between public health research funders and other relevant bodies, as well as academia, in order to establish synergies and avoid duplication. It will further facilitate the development of a strategic research agenda taking into account the diversity which exists within Europe. This agenda will identify at least a number of measurable, performance enhancing, scientific-technological or socio-economic objectives, supported by an appropriate analysis.
Финансирование: 1-2 млн. евро.
Двухэтапные конкурсы
Крайний срок подачи заявки на 1 этап 04 октября 2016 года
Крайний срок подачи заявок на 2 этап (в случае выигрыша заявки на 1 этапе) 11 апреля 2017 года)
SC1-PM-02-2017: New concepts in patient stratification
Proposals should deliver novel concepts for disease-mechanism based patient stratification to address the needs for stratified or personalised therapeutic interventions. The proposals should integrate multidimensional and longitudinal data and harness the power of -omics, including pharmacogenomics, systems biomedicine approaches, network analysis and of computational modelling. The new concepts of stratification should be validated in pre-clinical and clinical studies taking into account sex and gender differences. Applicants are encouraged to actively involve patient associations. The proposals should consider regulatory aspects of clinical practice and commercialisation opportunities. Proposals should focus on complex diseases having high prevalence and high economic impact.
SC1-PM-07–2017: Promoting mental health and well-being in the young
Proposals should develop population-oriented primary prevention15 interventions to promote mental well-being of young people and assess them for their effectiveness. The interventions should build on but may go beyond existing state-of-the art knowledge on biological, psychological and social determinants of mental well-being such as societal, cultural, work life, lifestyle, epidemiological, economic and environmental perspectives. The proposals should aim at increasing resilience and mitigating the impact of biological, psychosocial and environmental risk factors. The target group should include young up to 25 years (or a subgroup there of), which is an age limit often used as many severe disorders start in this period.
The research design should be developed by means of a multidisciplinary approach and involve the young themselves and other relevant stakeholders. Innovative approaches in involving the young and gathering their inputs for the design of the intervention should be considered. The interventions should use a holistic approach, taking gender and health inequality aspects into account, in increasing resilience and empowering the young. The interventions to be developed should reflect the diversity of the different countries and regions in Europe and beyond. The research should pay particular attention to ethical issues. The interventions should be assessed for mental well-being outcomes as well as the economic and social benefits and impact on reducing inequalities. These analyses of impact and effectiveness should be presented in quantitative as well as qualitative terms, in a gender disaggregated way where relevant. The results should be disseminated throughout Europe and beyond in order that the evidence generated is fully exploited.
SC1-PM-08–2017: New therapies for rare diseases
Support will be provided to clinical trials on substances where orphan designation has been given by the European Commission, where the proposed clinical trial design takes into account recommendations from protocol assistance given by the European Medicines Agency, and where a clear patient recruitment strategy is presented. Clinical trials may focus on a range of interventions with an orphan designation, from small molecule to gene or cell therapy, may include novel interventions and/or repurposing of existing and known interventions. The intervention must have been granted the EU orphan designation at the latest on the date of the full proposal call closure. A concise feasibility assessment justified by available published and preliminary preclinical or clinical results and supporting data shall also be provided. Appropriate plans to engage with patient organisations, Member States health authorities and considerations of efficacy/potential clinical benefit as well as early indication on health economics should be integrated in the application. In addition to the clinical trial, proposals may also include limited elements of late stage preclinical research and/or experimental evaluation of potential risks which must be complementary/contribute to the clinical trial(s) carried out within the proposal. The centre of gravity must clearly be the clinical trial(s). The participation of SMEs is encouraged.
Selected proposals shall contribute to the objectives of, and follow the guidelines and policies of the International Rare Diseases Research Consortium, IRDiRC (www.irdirc.org).
SC1-PM-10–2017: Comparing the effectiveness of existing healthcare interventions in the adult population
Proposals should compare the use of currently available preventative or therapeutic (pharmacological as well as non-pharmacological) healthcare interventions in adults19. While there is no restriction on the diseases or interventions to be the focus of proposals, preference will be given to proposals focusing on interventions with high public health relevance and socio-economic impact, i.e. interventions addressing conditions that are particularly frequent, may lead to co-morbidities, have a high negative impact on the quality of life of the individual and/or are associated with significant costs or where savings can be achieved. A cost effectiveness analysis must be included. Given the focus on existing interventions, proposals will aim to contribute to improve interventions, take decisions about the discontinuation of interventions that are less effective or less cost-effective than others, and make recommendations on the most effective and cost-effective approaches. A comprehensive array of clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, morbidity, costs, and performance of the health systems) for chosen populations should be assessed. Agreed core outcome sets (COS) should be used as endpoints in conditions where they already exist, in other cases efforts should be made to agree on such COS. Randomised controlled trials, pragmatic trials, observational studies, large scale databases and meta-analyses may be considered for this topic. Where relevant the study population should address gender as well as socio-economic differentials in health and/or any other factors that affect health equity.
